证券代码： 301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 编号：20230516 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | 新闻发布会 路演活动 □ □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 16 日 (周二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事、总经理：孙庆民 | | 员姓名 | 2、董事、副总经理、董事会秘书：王荣海 | | | 3、独立董事：朱清滨 | | | 4、副总经理、财务总监：杨善国 | | | 5、保荐代表人：孔辉焕 投资者提出的问题及公司回复情况 | | | 1、领导下午好！请问公司关于股权激励方面有没什么新的进 | | | 公司就投资者在本次 ...

证券代码：301069 证券简称：凯盛新材 公告编号：2023-036 山东凯盛新材料股份有限公司 关于召开2022年年度报告业绩网上说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、会议召开情况 山东凯盛新材料股份有限公司（以下简称"公司"）将于 2023 年 5 月 16 日（星 期二）下午 15:00-17:00 在"全景网"提供的平台举行《2022 年年度报告》网上业 绩说明会，投资者可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与 本次说明会。公司《2022 年年度报告》及其摘要已刊登在《中国证券报》、《证 券时报》、《证券日报》、《上海证券报》和巨潮资讯网（www.cninfo.com.cn），敬 请投资者查阅。 二、参会人员 出席本次年度报告业绩网上说明会的人员包括： 4、杨善国先生（财务总监） 5、孔辉焕先生（保荐代表人） 欢迎广大投资者积极参与本次业绩说明会！ 三、问题征集 投资者可扫描下方二维码预先提出问题： - 1 - 1、孙庆民先生（董事、总经理） 2、王荣海先生（董事、董事会秘书 ...

Financial Performance - The company's revenue for Q1 2023 was ¥248,028,189.67, a decrease of 3.82% compared to ¥257,889,942.36 in the same period last year[5] - Net profit attributable to shareholders was ¥50,672,203.78, down 26.39% from ¥68,837,886.38 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 248,028,189.67, a decrease of 3.34% compared to CNY 257,889,942.36 in Q1 2022[22] - Net profit for Q1 2023 was CNY 50,609,357.55, down 26.54% from CNY 68,837,886.38 in the same period last year[23] - The total comprehensive income for Q1 2023 was ¥50,609,357.55, down from ¥68,837,886.38 in Q1 2022[24] Cash Flow - The net cash flow from operating activities was -¥53,679,767.28, representing a decline of 109.97% compared to -¥25,565,492.63 in the previous year[5] - Cash inflow from operating activities totaled ¥96,333,280.23, a decline of 13.3% from ¥111,051,731.17 in Q1 2022[26] - Cash and cash equivalents at the end of Q1 2023 were ¥172,357,639.45, down from ¥303,024,322.61 at the end of Q1 2022, representing a decrease of 43.1%[28] - The company reported cash outflows from investing activities of ¥191,577,216.61, compared to ¥401,722,911.91 in the previous year, indicating a significant reduction in investment spending[27] - The net cash flow from investing activities was -¥16,254,776.14, contrasting with a positive cash flow of ¥128,024,770.41 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.95% to ¥1,717,809,048.67 from ¥1,668,525,610.49 at the end of the previous year[5] - Accounts receivable rose to CNY 93,194,426.32, an increase of 25.49% from CNY 74,257,599.33 at the beginning of the year[20] - Cash and cash equivalents decreased to CNY 172,357,639.45 from CNY 242,320,450.51, a decline of 28.83%[20] - Inventory increased to CNY 54,553,932.35, up 28.43% from CNY 42,504,525.44 at the beginning of the year[20] - Total liabilities remained relatively stable at CNY 247,682,415.89, compared to CNY 247,635,312.42 at the beginning of the year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,470, with the largest shareholder holding 44.51% of the shares[14] - Major shareholders include Huabang Life Health with 187,216,000 shares and CITIC Securities with 13,712,000 shares, all classified as pre-IPO restricted shares[17] - The total number of restricted shares at the beginning of the period was 280,200,000, with no new restrictions added during the quarter[17] - The top ten unrestricted shareholders hold a total of 18,193,600 shares, with Hongxin Guotai (Beijing) Investment Co., Ltd. being the largest[15] - The total number of unrestricted shares held by the top ten shareholders is 18,193,600, representing a significant portion of the company's equity[15] Expenses - Total operating costs increased to CNY 189,232,030.29 from CNY 178,678,210.88, reflecting a rise of 5.77%[23] - Research and development expenses increased by 53.60% to ¥1,430,000.00, reflecting the company's commitment to innovation[11] - Management expenses rose by 51.92% to ¥1,600,000.00, primarily due to increased equity incentive costs and depreciation[11] - Research and development expenses for Q1 2023 were CNY 14,307,857.49, compared to CNY 9,314,962.01 in Q1 2022, marking a 53.06% increase[23] Share Performance - The company's weighted average return on equity decreased to 3.51% from 5.26% year-on-year[5] - The basic and diluted earnings per share for Q1 2023 were both ¥0.1205, down from ¥0.1637 in the same period last year[24] Investment Income - The company experienced a 44.67% decrease in investment income, down ¥483,900.00, attributed to reduced returns from financial investments[11] - The company reported a 30.27% decrease in trading financial assets, down ¥64,726,500.00, due to reduced investment holdings to meet operational funding needs[10] Other Information - The company has not disclosed any new strategies or market expansions in the current report[18] - The company has not reported any new product developments or technological advancements in this quarter[18] - The company has no new developments or changes in the number of preferred shareholders during the quarter[16] - There are no changes in the number of restricted shares for major shareholders during the quarter[17] - The report indicates that the release date for restricted shares is set for September 27, 2024[17] - The company did not report any audited financial results for the first quarter[29]

Financial Performance - The company's operating revenue for 2022 was CNY 1,010,484,930, representing a 14.88% increase compared to CNY 879,591,549 in 2021[20] - The net profit attributable to shareholders for 2022 was CNY 234,523,025, a 21.28% increase from CNY 193,379,072 in the previous year[20] - The net profit after deducting non-recurring gains and losses was CNY 226,421,389, which is a 25.95% increase from CNY 179,772,058 in 2021[20] - The total assets at the end of 2022 amounted to CNY 1,668,525,610, reflecting a 17.29% increase from CNY 1,422,613,681 at the end of 2021[20] - The basic earnings per share for 2022 was CNY 0.5575, an increase of 8.29% compared to CNY 0.5148 in 2021[20] - The company reported a total of 8,101,636.32 yuan in non-recurring gains and losses for 2022, a decrease from 13,607,013.54 yuan in 2021, indicating a decline of approximately 40.5%[26] - The company reported a gross profit margin of 39.02% for the chemical new materials sector, an increase of 2.24% compared to the previous year[63] - The company reported a significant increase in user data, reflecting a growing customer base and market demand for its products[126] Cash Flow and Investments - The cash flow from operating activities showed a significant decline, with a net outflow of CNY 10,444,069, down 88.22% from CNY 88,631,424 in the previous year[20] - Operating cash inflow totaled ¥548,206,165.34 in 2022, a 12.66% increase compared to ¥486,598,692.60 in 2021[76] - The net cash flow from operating activities decreased by 88.22% to ¥10,444,069.03, primarily due to increased construction and equipment payments[76] - Investment cash inflow surged by 212.75% to ¥2,158,855,085.36, compared to ¥690,287,142.33 in 2021[76] - The total investment amount for the reporting period was ¥16,195,665.20, reflecting a 54.24% increase compared to the previous year's investment of ¥10,500,000.00[82] - The company raised a total of CNY 31,020.00 million through the issuance of 60 million shares, with a net amount of CNY 28,189.15 million after expenses[89] - The company has committed to invest CNY 23,189.15 million in a 2,000 tons/year polyether ketone resin project, with 100% of the investment completed by November 30, 2022[91] Research and Development - The company’s R&D strategy is aligned with national innovation-driven development, focusing on market trends and customer needs to drive product innovation[32] - The company has a strong technical foundation with over 139 patents, including 88 invention patents, and a research team of 204 personnel, enhancing its competitive edge in the chemical industry[36] - The company is developing an automated distillation process for acyl chloride products, aiming to improve efficiency and reduce production costs[71] - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability[182] - The number of R&D personnel increased by 33.33% from 153 in 2021 to 204 in 2022, with a proportion of 27.27% of total employees[74] Production and Capacity - Chlorinated steel production capacity is designed at 150,000 tons/year with a utilization rate of 94.24%[46] - The production capacity for isophthaloyl chloride is 31,000 tons/year with a utilization rate of 76.31%, and a new project of 20,000 tons/year is under construction[46] - The production capacity for PEKK is 100 tons/year with a utilization rate of 11.00%, and an additional 1,000 tons/year production facility is currently in trial production[46] - The company is actively expanding its production capacity, with a new chlorinated acetyl chloride project entering trial production in February 2023[47] Market and Sales - The company’s overseas sales revenue accounted for 13.80% of total operating income in 2022, indicating a strong presence in international markets[34] - Domestic sales reached CNY 871,079,880.70, making up 86.20% of total revenue, while international sales surged by 127.11% to CNY 139,405,049.30[61] - The chemical new materials segment contributed CNY 982,438,338.15, accounting for 97.22% of total revenue, with a year-on-year growth of 12.43%[60] Governance and Compliance - The company has maintained a consistent governance structure, with independent directors ensuring compliance and oversight[130] - The company established an internal control system to ensure compliance with laws and regulations, enhancing operational management and risk control[113] - The company has no significant discrepancies in governance compared to regulations set by the China Securities Regulatory Commission[116] - The company held one annual and two temporary shareholder meetings during the reporting period, ensuring compliance with legal requirements[110] Environmental and Safety Management - The company has established a comprehensive safety and environmental management system, ensuring stable operations through regular safety training and inspections[37] - The company is committed to technological innovation, focusing on the recycling and utilization of sulfur dioxide, contributing to a green economy[38] - The company has implemented a comprehensive environmental monitoring plan, ensuring compliance with discharge standards[163] - The company has established an emergency response plan for environmental incidents, enhancing its ability to prevent and manage such events[162] Employee and Management - The total remuneration for directors, supervisors, and senior management in 2022 amounted to CNY 6.8025 million, reflecting a performance-based compensation structure[132] - The company has a clear remuneration policy linked to performance, ensuring alignment of interests between management and shareholders[131] - The company plans to enhance employee training programs in 2023, focusing on operational management and skill development to improve overall competitiveness[143] Strategic Outlook - The company aims to achieve a revenue growth target of 15% by 2025, indicating a strong outlook for future performance[124] - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 500 million RMB allocated for this purpose[181] - The company is committed to maintaining compliance with regulatory standards to avoid any potential legal issues related to its operations[181]

编号：20211102 证券代码：301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 分析师会议 | | 投资者关系 | 业绩说明会 | | 活动类别 | 路演活动 | | | | | | | | | 海通证券、东方证券、中泰证券、天风证券、广发证券、国元证 | | 参与单位名称 及人员姓名 | 券、西南证券、西部证券、国泰君安证券、华金证券、平安资产、 睿远基金、大朴资产、中庚基金、中海基金、大成基金、中欧基 金、上投摩根基金、东证资管、上海瑞杨投资、混沌投资、西安 | | | 瀑布资产管理有限公司、青岛朋元资产管理有限公司 | ...

编号：20220516 证券代码：301069 证券简称：凯盛新材 山东凯盛新材料股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------------|----------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | | | 南方基金、混沌资产、富国基金、中欧基金、工银瑞信、易方达基金、 | | 参与单位名称及 | | 宝盈基金、盘京投资、交银施罗德、兴业基金、汇丰晋信、华安基金、 | | 人员姓名 | | 天弘基金、长城基金、融通基金、国海富兰克林、长江养老保险、申 | | | | 万菱信基金、圆信永丰、源乐晟招银理财、恒睿信投资、丰奘投资 | | 时间 | 2022 年 5 月 9 日-5 月 | 14 日 | | 地点 | | 线上（腾讯 ...

证券代码：301069 证券简称：凯盛新材 公告编号：2022-042 山东凯盛新材料股份有限公司 关于参加山东辖区上市公司2022年度投资者网上 集体接待日活动的通知公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步做好投资者关系管理工作，增强与广大投资者的互动交流，山东凯 盛新材料股份有限公司（以下简称"公司"）将参加由山东证监局、山东上市公 司协会联合深圳市全景网络有限公司举办的"山东辖区上市公司 2022 年度投资 者网上集体接待日活动"（以下简称"本次活动"），现将有关事项公告如下： 1. 本次活动的时间：2022 年 11 月 16 日（星期三）下午 14:00-16:00。 2. 本次活动的交流网址：本次活动将通过深圳市全景网络有限公司提供的 网上平台，采取网络远程的方式进行，投资者可以登陆全景网"全景·路演天下" （http://rs.p5w.net）进入专区页面参与交流。 3. 公司出席本次活动的相关人员： （1）王荣海先生（董事、副总经理、董事会秘书） （2）杨善国先生（副总经理、财务总监） 4. 届时以上公司领导将通过网络在线交流 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 399,443,228.84, representing a 31.05% increase compared to the same period last year[27]. - The net profit attributable to shareholders of the listed company was CNY 94,965,761.61, reflecting a growth of 38.27% year-on-year[27]. - The net profit after deducting non-recurring gains and losses was CNY 92,250,317.16, which is a 35.11% increase compared to the previous year[27]. - The basic earnings per share increased by 18.57% to CNY 0.2633[27]. - The company's operating revenue for the current period reached ¥523,488,303.52, representing a year-on-year increase of 31.05% due to higher product prices and increased sales volume of aramid polymer monomers[50]. - The total operating revenue for the first half of 2022 was CNY 523,488,303.52, an increase from CNY 399,443,228.84 in the same period of 2021, representing a growth of approximately 31.1%[188]. - The company's net profit for the first half of 2022 was CNY 131,313,607.79, an increase of 38.2% compared to CNY 94,965,761.61 in the same period of 2021[195]. - The company's operating profit was CNY 159,898,623.89, compared to CNY 114,208,982.04 in the prior year, reflecting a growth of 40.0%[199]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,422,613,681.07, up 5.20% from the end of the previous year[27]. - The total assets as of June 30, 2022, amounted to CNY 1,457,460,160.04, compared to CNY 1,422,037,260.76 at the beginning of the year, reflecting a growth of approximately 2.5%[188]. - The total liabilities as of June 30, 2022, were CNY 128,699,863.40, slightly up from CNY 127,937,913.55 at the beginning of the year[188]. - The company's total liabilities included accounts payable of ¥147,417,319.04, which increased from ¥99,106,607.54, indicating a rise of approximately 48.7%[179]. Cash Flow - The net cash flow from operating activities decreased significantly by 149.55% to CNY 34,399,917.53[27]. - The net cash flow from operating activities was -¥17,046,096.74, a significant decrease of 149.55% compared to the previous year, influenced by increased cash payments for goods procurement[50]. - The company's cash and cash equivalents increased by 246.87% to ¥47,964,744.26, mainly due to net redemptions of financial products based on operational funding needs[50]. - The cash and cash equivalents increased to CNY 244,491,708.32 from CNY 196,298,048.84, marking a rise of approximately 24.5%[185]. Research and Development - Research and development expenses increased by 14.70% to ¥18,405,730.82, mainly due to rising prices of bulk raw materials and energy[50]. - Research and development expenses increased to CNY 18,405,730.82, representing a rise of 14.7% from CNY 16,046,200.44 in the previous year[196]. - The company holds 137 valid patents, including 86 invention patents, and has established various innovation platforms such as a national postdoctoral research station and a national enterprise technology center[43]. Environmental and Safety Management - The company emphasizes safety and environmental management, ensuring stable operations through rigorous safety training and compliance with production standards[38]. - The company has implemented a wastewater treatment system that meets the standards of GB31573-2015 and GB/T31962-2015, ensuring compliance with discharge regulations[102]. - The average concentration of COD in wastewater is 40.7 mg/L, and ammonia nitrogen is 2.36 mg/L, both below the allowable limits of 500 mg/L for COD and 45 mg/L for ammonia nitrogen[99]. - The company has established dedicated departments for safety and environmental management to ensure compliance with regulations[85]. - The company has enhanced its environmental protection efforts, ensuring all pollutants met discharge standards during the reporting period[116]. Strategic Initiatives - The company has formed a development strategy that extends from fine chemicals to high-performance polymer materials, enhancing overall competitiveness[45]. - The company has implemented a core technology for the separation and recycling of sulfur dioxide, reducing production costs and addressing environmental concerns[44]. - The company has established stable relationships with high-quality customers, including major aramid producers like DuPont, Teijin, and Kolon[47]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company held its annual general meeting on April 8, 2022, with a participation rate of 74.89%[90]. - The company approved a restricted stock incentive plan on April 11, 2022, proposing to grant a total of 2.176 million shares, with 1.976 million shares allocated to 201 incentive recipients and 200,000 shares reserved[95]. - The total number of shares is 420,640,000, with 360,640,000 shares subject to restrictions, representing 85.74%[149]. Risks and Challenges - The company faces significant risks from raw material price fluctuations, as raw materials account for a large proportion of the main business costs, impacting gross margins[81]. - Environmental policy risks are increasing, with potential additional investments required to meet stricter regulations, which could raise operational costs[85]. - The company anticipates potential increases in production costs due to energy substitution policies, but has prepared by building a natural gas boiler as a backup[86]. Community Engagement - The company donated RMB 1 million and over RMB 50,000 worth of protective materials to support local pandemic prevention efforts[113].

Financial Performance - The company's operating revenue for Q1 2022 was ¥257,889,942.36, representing a 31.35% increase compared to ¥196,335,886.00 in the same period last year[4] - Net profit attributable to shareholders was ¥68,837,886.38, up 33.58% from ¥51,532,054.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥67,103,847.65, reflecting a 33.71% increase from ¥50,184,657.21 in the previous year[4] - Operating profit for the quarter was ¥82,643,519.25, representing a year-on-year increase of 34.4% from ¥61,442,743.98[32] - The net profit for the current period is 68,837,886.38, compared to 51,532,054.43 in the previous period, representing a growth of approximately 33.5%[35] - Basic earnings per share increased to 0.1637 from 0.1429, reflecting a rise of about 17.5%[35] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥25,565,492.63, a significant decrease of 243.49% compared to a net inflow of ¥17,817,167.60 in the same period last year[4] - Cash inflow from operating activities totaled 111,051,731.17, up from 104,546,329.66, indicating an increase of approximately 6.4%[39] - Cash outflow from operating activities rose to 136,617,223.80 from 86,729,162.06, resulting in a net cash flow from operating activities of -25,565,492.63, compared to 17,817,167.60 in the previous period[39] - The net increase in cash and cash equivalents for the current period was 102,426,479.43, compared to a decrease of -23,649,155.33 in the previous period[42] - The ending balance of cash and cash equivalents reached 303,024,322.61, up from 158,090,558.38, indicating a growth of approximately 91.5%[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,499,796,542.20, an increase of 5.43% from ¥1,422,613,681.07 at the end of the previous year[4] - Total liabilities amounted to ¥154,620,823.62, up from ¥147,569,613.39, reflecting a rise of 4.3%[24] - Non-current assets totaled ¥578,619,908.22, up from ¥526,091,085.17, showing a growth of 10%[24] - Cash and cash equivalents at the end of the period totaled ¥303,024,322.61, up from ¥200,597,843.18 at the beginning of the year, reflecting a 50.9% increase[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,073[12] - The largest shareholder, Huabang Life Health Co., Ltd., holds 44.51% of shares, totaling 187,216,000 shares[12] - The second-largest shareholder, Zibo Kaisheng Investment Management Center, holds 6.79% of shares, totaling 28,571,200 shares[12] - The company has a total of 364,305,348 shares, with 360,640,000 shares remaining under lock-up conditions[19] - The total number of shares held by the top ten shareholders includes significant stakes from various investment firms and individuals, indicating strong institutional support[12] Operational Developments - The company’s technology center was recognized as a national enterprise technology center in 2021[20] - The company is constructing a new production base in Weifang, which officially commenced on February 12, 2022[20] Other Expenses - The company reported a significant increase in sales expenses by 119.00% to ¥258,000, attributed to higher export business costs[7] - Other operating expenses increased by 196.43% to ¥95,140, primarily due to a donation of ¥1,000,000 to a charity for epidemic prevention[10] Share Issuance and Restrictions - The company has no new shares issued during the reporting period, maintaining the same number of restricted shares[16] - The company plans to lift restrictions on certain shares on September 27, 2022, and September 27, 2024, for various shareholders[16] - The company has not reported any changes in the number of restricted shares during the current period[19] Comprehensive Income - The company reported a total comprehensive income of 68,837,886.38, which is the same as the net profit, indicating no other comprehensive income items for the period[35] Audit Status - The company has not undergone an audit for the first quarter report[43]

Financial Performance - The company's operating revenue for 2021 was ¥879,591,549.14, representing a 40.95% increase compared to ¥624,026,860.13 in 2020[25] - The net profit attributable to shareholders for 2021 was ¥193,379,071.90, which is a 20.50% increase from ¥160,480,613.99 in 2020[25] - The net profit after deducting non-recurring gains and losses was ¥179,772,058.36, up 13.91% from ¥157,818,314.46 in 2020[25] - The total assets at the end of 2021 reached ¥1,422,613,681.07, a 57.40% increase from ¥903,824,701.09 at the end of 2020[25] - The net assets attributable to shareholders increased by 59.84% to ¥1,275,044,067.68 at the end of 2021 from ¥797,702,313.28 at the end of 2020[25] - The basic earnings per share for 2021 was ¥0.5148, reflecting a 15.69% increase from ¥0.4450 in 2020[25] - The net cash flow from operating activities decreased by 36.66% to ¥88,631,424.00 in 2021 from ¥139,935,143.91 in 2020[25] - The weighted average return on equity for 2021 was 20.04%, down from 22.04% in 2020[25] Revenue and Sales - The company's total revenue for Q4 was ¥278,042,348.33, showing a significant increase compared to Q1's ¥196,335,886.00[28] - The net profit attributable to shareholders for Q4 was ¥51,711,693.62, which is an increase from Q2's ¥43,433,707.18[28] - The net cash flow from operating activities in Q4 reached ¥38,378,596.53, a notable rise from Q1's ¥17,817,167.60[28] - Chlorosulfonic acid revenue reached CNY 295.93 million, accounting for 33.64% of total revenue, with a year-over-year growth of 63.72%[83] - Domestic sales contributed CNY 818.21 million, representing 93.02% of total revenue, with a year-over-year increase of 55.21%[86] Production and Capacity - The company is expanding its production capacity with the new Weifang production base and the mass market introduction of new products like polyether ketone[38] - The production capacity utilization rate for chlorosulfonic acid is 90.02%, with a designed capacity of 150,000 tons per year[67] - The company is in the industrial production stage for key products such as chlorosulfonic acid and aramid polymer monomer, with ongoing technology iterations[67] - The company has initiated trial production for a new project with a capacity of 10,000 tons per year for isophthaloyl chloride, which began in February 2022[69] - The company is expanding its production capabilities with a new project for high-purity 2-propoxyethyl chloride, which is currently in trial production[71] Research and Development - The company has a strong R&D team with 157 personnel, including 3 PhDs and 7 Master's degree holders, focusing on high-end chemical products and has 139 patents, of which 86 are invention patents[45] - The company has established various innovation platforms, including a national postdoctoral research station and a national enterprise technology center, enhancing its R&D capabilities[45] - The company is committed to continuous investment in new product development to ensure the commercialization of research outcomes[45] - The number of R&D personnel increased by 64.52% from 93 in 2020 to 153 in 2021, with R&D personnel accounting for 24.84% of the total workforce[104] - R&D investment amounted to ¥43,096,738.38 in 2021, representing 4.90% of operating revenue, an increase from 4.74% in 2020[104] Market and Sales Strategy - The company has established strong relationships with key clients, including DuPont and Teijin, enhancing its market presence in regions such as China, Japan, South Korea, and the United States[81] - The company is focused on optimizing its production processes and has developed a circular economy model for sulfur dioxide, reducing environmental impact and production costs[78] - The company aims to establish a comprehensive industrial chain from basic chemical raw materials to high-performance polymer materials, targeting four downstream industries: new pigments, new pesticides, new materials, and new energy[140] - The company plans to enhance its product structure and increase production capacity for core products while improving product quality and reducing energy consumption[141] Financial Management - The total investment amount during the reporting period was ¥10,500,000, a 100% increase compared to the same period last year[118] - The company made a significant equity investment of ¥10,500,000 in Shandong Research Institute of High-Performance Materials, acquiring a 35% stake[118] - The company reported a loss of ¥133,678.88 from the investment in Shandong Research Institute of High-Performance Materials[118] - The total amount of raised funds was ¥31,020,000, with ¥4,277,100 utilized during the reporting period[123] - The remaining unused raised funds amount to ¥24,008,320, which are temporarily managed as cash[123] Governance and Compliance - The company has established an internal control system to manage risks and ensure normal business operations[154] - The company maintains transparency in information disclosure, adhering to relevant regulations and ensuring fair access to information for all shareholders[155] - The actual controller of the company exercises rights and obligations without occupying company funds or exceeding authority[151] - The company has no significant differences in governance compared to regulations set by the China Securities Regulatory Commission[158] - The company has a complete and independent business operation capability, independent of the controlling shareholder[159] Employee and Management - The total number of employees at the end of the reporting period was 616[199] - The management team includes professionals with advanced degrees and certifications, such as senior engineers and accountants, ensuring a high level of expertise[170] - The company has appointed independent directors with significant experience in finance and law, enhancing governance and oversight[171] - The total remuneration for directors, supervisors, and senior management in 2021 amounted to CNY 5.4499 million, which is linked to their positions and performance evaluations[180] - Wang Jiarong, the Chairman and General Manager, received a pre-tax total remuneration of CNY 1.6483 million in 2021[183]